I received a googe alert on pharmacogenetics from this blog the other day. A great explanation of the therapeutic window for the layman.
Filed under: Recommended Links
-
-
Recent Comments
pubmed: Cytochrome P450 Huma…- [Pharmacogenetics/pharmacogenomics in psychiatry]
- Drug interactions evaluation: an integrated part of risk assessment of therapeutics.
- Genetic polymorphisms of CYP2D6*10 and CYP2C19*2, *3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen.
- Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD.
- The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline.
- pubmed: Pharmacogenetics Hum…
- pubmed: Drug Interactions Hu…
One Response
Leave a Reply
Calendar
Recommended Books
Recommended Sites
Many thanks for including me in your posting, will be adding more on pharmacogenetics at CorePsychBlog, as it has been my favorite subject for > 10 years, most especially regarding the comorbidity of depression and ADD, and the mixing of drugs for those problems.
My big pet peeve is 2D6 blockage by prozac and paxil, two major inhibitors with AMP [from dexedrine to adderall to vyvanse - all substrates] as interaction sites… often months down the line, but quite frequently right out of the box. -See it all the time, have been onto it for years, many aren’t looking as carefully as they should, with subsequent problems.
Then right behind that is the genetic polymorphism issue with 2D6, also not the radar sufficiently.
Thanks again,
Chuck